News: Ab Science SA (ABS.PA)

ABS.PA on Paris Stock Exchange

16.86EUR
27 May 2015
Change (% chg)

-- (--)
Prev Close
€16.86
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
94,567
52-wk High
€18.93
52-wk Low
€7.16

Search Stocks
Select another date:

BRIEF-Ab Science Mastinib in peripheral t-cell lymphoma accelerated into phase 3

* Phase 2 with Masitinib in peripheral T-cell lymphoma accelerated into phase 3

BRIEF-AB Science announces new U.S. patent for masitinib in treatment of asthma

* Announces issuance of a new U.S. patent for masitinib in the treatment of severe persistent asthma

BRIEF-Ab Science FY net loss widens to 16.1 million euros

* FY net loss of 16.1 million euros ($18.0 million) versus loss of 14.6 million euros year ago

BRIEF-Results of Ab Science's Masitinib treatment to be published in Annals of Oncology

* The phase III results of the Masitinib treatment of advanced pancreatic cancer to be published in Annals of Oncology Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Ab Science DSMB recommends continuation of phase II Masitinib study

* Announces that DSMB recommends the continuation of phase 2 study assessing Masitinib in relapsing head and neck cancer

BRIEF-Ab Science's Masitinib receives orphan drug designation for amyotrophic lateral sclerosis from FDA

* Masitinib receives orphan drug designation for amyotrophic lateral sclerosis from FDA

BRIEF-AB Science announces positive phase 2 clinical study of Masitinib

* Announces positive efficacy and safety results from phase 2 study with Masitinib in patients with triple negative breast cancer (TNBC) Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Ab Science Q4 revenue rises to 544,000 euros

* Q4 revenue of 544,000 euros ($608,736) versus 496,000 euros year ago

BRIEF-Ab Science announces positive Masitinib phase 2 results

* Announces positive phase 2 clinical study data of Masitinib in second-line metastatic stomach cancer

BRIEF-AB Science says DSMB recommends continuation of phase 3 study of masitinib in amyotrophic lateral sclerosis

* Data And Safety Monitoring Board (DSMB) recommends the continuation of phase 3 study of masitinib in amyotrophic lateral sclerosis

Select another date:
Search Stocks